Drug Trial Radar · NCT06626919
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 30, 2025
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.
Conditions
- Muscular Diseases
- Neuromuscular Manifestations
- Autoimmune
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Myasthenia Gravis
- Muscle Weakness
Interventions
anito-celBiological
Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
CyclophosphamideDrug
Administered intravenously
FludarabineDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)Time frame: First dose date up to 24 months
- Percentage of Participants Experiencing Dose-Limiting Toxicities (DLT)Time frame: Up to 28 days following anito-cel infusion
- Maximum Tolerated Dose (MTD) of Anito-celTime frame: First dose up to 30 days (Up to 24 months)
- Percentage of Participants With Laboratory AbnormalitiesTime frame: First dose date up to 24 months
- Recommended Phase 2 Dose (RP2D) of Anito-celTime frame: Up to 24 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
UC Irvine Medical Center
Orange, California · Recruiting
Stanford Blood and Marrow Transplant
Palo Alto, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare
Tampa, Florida · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University of Minnesota Delaware Clinical Research Unit
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Houston Methodist Hospital
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.